CA3068926A1 - Tissue scaffold - Google Patents
Tissue scaffold Download PDFInfo
- Publication number
- CA3068926A1 CA3068926A1 CA3068926A CA3068926A CA3068926A1 CA 3068926 A1 CA3068926 A1 CA 3068926A1 CA 3068926 A CA3068926 A CA 3068926A CA 3068926 A CA3068926 A CA 3068926A CA 3068926 A1 CA3068926 A1 CA 3068926A1
- Authority
- CA
- Canada
- Prior art keywords
- elastin
- cross
- composition
- linking
- scaffold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002407 tissue scaffold Substances 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 117
- 102000008186 Collagen Human genes 0.000 claims abstract description 74
- 108010035532 Collagen Proteins 0.000 claims abstract description 74
- 229920001436 collagen Polymers 0.000 claims abstract description 74
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 61
- 102000009123 Fibrin Human genes 0.000 claims abstract description 50
- 108010073385 Fibrin Proteins 0.000 claims abstract description 50
- 229950003499 fibrin Drugs 0.000 claims abstract description 50
- 229920002549 elastin Polymers 0.000 claims description 382
- 108010014258 Elastin Proteins 0.000 claims description 362
- 102000016942 Elastin Human genes 0.000 claims description 357
- 239000000203 mixture Substances 0.000 claims description 112
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 87
- 238000004132 cross linking Methods 0.000 claims description 79
- 239000003431 cross linking reagent Substances 0.000 claims description 40
- 235000006408 oxalic acid Nutrition 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 210000001519 tissue Anatomy 0.000 claims description 22
- 238000005406 washing Methods 0.000 claims description 22
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 15
- 239000003638 chemical reducing agent Substances 0.000 claims description 13
- 230000017423 tissue regeneration Effects 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000017 hydrogel Substances 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 9
- 150000001299 aldehydes Chemical class 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 7
- 230000035876 healing Effects 0.000 claims description 7
- 239000012279 sodium borohydride Substances 0.000 claims description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 7
- 238000010382 chemical cross-linking Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000010899 nucleation Methods 0.000 claims description 4
- 230000008929 regeneration Effects 0.000 claims description 4
- 238000011069 regeneration method Methods 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 210000004872 soft tissue Anatomy 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 230000009257 reactivity Effects 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000011148 porous material Substances 0.000 description 36
- 239000000047 product Substances 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000015556 catabolic process Effects 0.000 description 14
- 238000006731 degradation reaction Methods 0.000 description 14
- 230000002792 vascular Effects 0.000 description 12
- 239000012620 biological material Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 108010049003 Fibrinogen Proteins 0.000 description 6
- 102000008946 Fibrinogen Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 229940012952 fibrinogen Drugs 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000008241 heterogeneous mixture Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000001878 scanning electron micrograph Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 5
- 102100033167 Elastin Human genes 0.000 description 5
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000003828 downregulation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000003041 ligament Anatomy 0.000 description 5
- 238000010872 live dead assay kit Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000004626 scanning electron microscopy Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 4
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 3
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 3
- 101000976622 Homo sapiens Zinc finger protein 42 homolog Proteins 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 3
- 102100023550 Zinc finger protein 42 homolog Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006065 biodegradation reaction Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000005266 casting Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 2
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 2
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 101710150336 Protein Rex Proteins 0.000 description 2
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 description 2
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000003349 alamar blue assay Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000001656 angiogenetic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 230000030944 contact inhibition Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229940015043 glyoxal Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- BWPAACFJSVHZOT-RCBQFDQVSA-N (2s)-1-[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-3-methylbutanoyl]amino]acetyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O BWPAACFJSVHZOT-RCBQFDQVSA-N 0.000 description 1
- LFTRJWKKLPVMNE-RCBQFDQVSA-N 2-[[(2s)-2-[[2-[[(2s)-1-[(2s)-2-amino-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-methylbutanoyl]amino]acetic acid Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O LFTRJWKKLPVMNE-RCBQFDQVSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 101600123942 Bos taurus Elastin (isoform 1) Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101150108568 ELN gene Proteins 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- -1 Gly-Val-Gly-Val-Pro Chemical class 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000691618 Homo sapiens Inactive phospholipase C-like protein 1 Proteins 0.000 description 1
- 102100026207 Inactive phospholipase C-like protein 1 Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101150101095 Mmp12 gene Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical class C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000035557 fibrillogenesis Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010069589 glycyl-valyl-glycyl-valyl-proline Proteins 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- AFEQENGXSMURHA-UHFFFAOYSA-N oxiran-2-ylmethanamine Chemical class NCC1CO1 AFEQENGXSMURHA-UHFFFAOYSA-N 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920000848 poly(L-lactide-ε-caprolactone) Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- PWEBUXCTKOWPCW-UHFFFAOYSA-N squaric acid Chemical compound OC1=C(O)C(=O)C1=O PWEBUXCTKOWPCW-UHFFFAOYSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000004506 ultrasonic cleaning Methods 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/56—Fibrin; Thrombin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2537/00—Supports and/or coatings for cell culture characterised by physical or chemical treatment
- C12N2537/10—Cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Laser Surgery Devices (AREA)
- Surgical Instruments (AREA)
- Prostheses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1711360.6 | 2017-07-14 | ||
| GBGB1711360.6A GB201711360D0 (en) | 2017-07-14 | 2017-07-14 | Tissue scaffold |
| PCT/GB2018/052002 WO2019012295A1 (en) | 2017-07-14 | 2018-07-13 | TISSUE SCAFFOLDING |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3068926A1 true CA3068926A1 (en) | 2019-01-17 |
Family
ID=59713538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3068926A Pending CA3068926A1 (en) | 2017-07-14 | 2018-07-13 | Tissue scaffold |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11738112B2 (enExample) |
| EP (2) | EP4338764A3 (enExample) |
| JP (2) | JP2020526337A (enExample) |
| AU (2) | AU2018298970B2 (enExample) |
| CA (1) | CA3068926A1 (enExample) |
| ES (1) | ES2948984T3 (enExample) |
| GB (1) | GB201711360D0 (enExample) |
| WO (1) | WO2019012295A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110917398A (zh) * | 2019-12-09 | 2020-03-27 | 沛嘉医疗科技(苏州)有限公司 | 生物材料的抗氧化方法及生物材料 |
| GB202004902D0 (en) * | 2020-04-02 | 2020-05-20 | Univ Oxford Innovation Ltd | Methods and products |
| US12163957B2 (en) * | 2020-06-01 | 2024-12-10 | King Abdullah University Of Science And Technology | Methods for detecting his-tagged proteins using NTA probes and polyacrylamide gel electrophoresis |
| CN114767930B (zh) * | 2022-04-11 | 2023-09-22 | 山东大学齐鲁医院 | 一种3d纳米纤维海绵体、制备方法及在脊髓损伤修复领域的应用 |
| JP2025005175A (ja) | 2023-06-27 | 2025-01-16 | 日亜化学工業株式会社 | 酸化物蛍光体、及びそれを用いた発光装置 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2598423B1 (fr) * | 1985-03-01 | 1989-03-17 | Inst Nat Sante Rech Med | Produit a base d'elastine, procede pour sa preparation et ses applications biologiques, en particulier en tant que biomateriaux et supports artificiels |
| US5989244A (en) * | 1994-11-15 | 1999-11-23 | Gregory; Kenton W. | Method of use of a sheet of elastin or elastin-based material |
| US6706690B2 (en) | 1999-06-10 | 2004-03-16 | Baxter Healthcare Corporation | Hemoactive compositions and methods for their manufacture and use |
| US6638308B2 (en) | 1997-10-10 | 2003-10-28 | John D. Corbitt, Jr. | Bioabsorbable breast implant |
| US6069129A (en) * | 1998-03-13 | 2000-05-30 | Mrs, Llc | Elastin derived composition and method of using same |
| EP1403304B1 (en) | 2001-05-30 | 2008-08-27 | Keiichi Miyamoto | Crosslinked elastin and processes for its production |
| JP4030881B2 (ja) | 2003-01-08 | 2008-01-09 | ペンタックス株式会社 | 相対回動環状二部材のバヨネット構造 |
| ATE490792T1 (de) | 2003-03-31 | 2010-12-15 | Teijin Ltd | Geformter elastin-artikel und verfahren zu seiner herstellung |
| WO2006046626A1 (ja) | 2004-10-29 | 2006-05-04 | Kyushu Institute Of Technology | 水溶性エラスチンとその製造方法及びそれを含む食品と医薬 |
| US20070104692A1 (en) | 2005-11-07 | 2007-05-10 | Quijano Rodolfo C | Breast tissue regeneration |
| DE102006029605A1 (de) | 2006-06-26 | 2007-12-27 | Lazar, Harald, Dr. | Brustimplantat |
| ATE529070T1 (de) | 2006-07-31 | 2011-11-15 | Organogenesis Inc | Mastopexie- und brustrekonstruktionsprothesen |
| WO2008037028A1 (en) * | 2006-09-29 | 2008-04-03 | Martin Kean Chong Ng | Tropoelastin-based protoelastin biomaterials |
| SG174922A1 (en) | 2009-03-27 | 2011-11-28 | Ethicon Inc | Medical devices with galvanic particulates |
| WO2010110067A1 (ja) * | 2009-03-27 | 2010-09-30 | 株式会社マルハニチロ食品 | エラスチン及びコラーゲンを用いた架橋物及びその用途 |
| DK2550027T4 (da) | 2010-03-22 | 2019-05-13 | Allergan Inc | Tværbundne polysaccharid- og protein-polysaccharid-hydrogeler til blødvævsforøgelse |
| US20140005784A1 (en) | 2012-06-29 | 2014-01-02 | Allergan, Inc. | Textured prosthesis with reduced capsular contracture response |
| US9433489B2 (en) | 2013-03-12 | 2016-09-06 | Soft Tissue Regeneration, Inc. | Absorbable synthetic braided matrix for breast reconstruction and hernia repair |
| JP6143163B2 (ja) | 2013-03-22 | 2017-06-07 | 国立大学法人三重大学 | 弾性組織様構造体の製造方法 |
| AU2015353653A1 (en) | 2014-11-26 | 2017-06-15 | Integra Lifesciences Corporation | Process for preparing tissue regeneration matrix |
| US20180296313A1 (en) | 2015-09-23 | 2018-10-18 | Novus Scientific Ab | Three-dimensional medical implant for regeneration of soft tissue |
| IL281898B2 (en) | 2018-10-03 | 2024-09-01 | Estab Labs S A | Scaffolding for implantable medical devices and methods of use thereof |
| DK4126088T3 (da) | 2020-03-22 | 2025-10-20 | Collplant Ltd | Collagenbaserede formuleringer, der kan anvendes som bløde vævsfyldstoffer og/eller implantater |
-
2017
- 2017-07-14 GB GBGB1711360.6A patent/GB201711360D0/en not_active Ceased
-
2018
- 2018-07-13 EP EP23169720.2A patent/EP4338764A3/en active Pending
- 2018-07-13 ES ES18745693T patent/ES2948984T3/es active Active
- 2018-07-13 JP JP2020501365A patent/JP2020526337A/ja not_active Ceased
- 2018-07-13 AU AU2018298970A patent/AU2018298970B2/en active Active
- 2018-07-13 WO PCT/GB2018/052002 patent/WO2019012295A1/en not_active Ceased
- 2018-07-13 CA CA3068926A patent/CA3068926A1/en active Pending
- 2018-07-13 US US16/630,638 patent/US11738112B2/en active Active
- 2018-07-13 EP EP18745693.4A patent/EP3651817B1/en active Active
-
2023
- 2023-06-09 JP JP2023095521A patent/JP7693152B2/ja active Active
- 2023-07-10 US US18/349,192 patent/US20240165299A1/en active Pending
-
2024
- 2024-09-27 AU AU2024220141A patent/AU2024220141A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4338764A2 (en) | 2024-03-20 |
| US20240165299A1 (en) | 2024-05-23 |
| JP7693152B2 (ja) | 2025-06-17 |
| JP2020526337A (ja) | 2020-08-31 |
| GB201711360D0 (en) | 2017-08-30 |
| AU2018298970B2 (en) | 2024-07-04 |
| AU2018298970A1 (en) | 2020-01-30 |
| WO2019012295A1 (en) | 2019-01-17 |
| ES2948984T3 (es) | 2023-09-22 |
| JP2023105244A (ja) | 2023-07-28 |
| AU2024220141A1 (en) | 2025-01-30 |
| EP3651817A1 (en) | 2020-05-20 |
| EP3651817B1 (en) | 2023-05-03 |
| US11738112B2 (en) | 2023-08-29 |
| EP4338764A3 (en) | 2024-06-05 |
| US20200164104A1 (en) | 2020-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240165299A1 (en) | Tissue scaffold | |
| CA2701858C (en) | Method for preparing porous scaffold for tissue engineering, cell culture and cell delivery | |
| Ma et al. | Enhanced biological stability of collagen porous scaffolds by using amino acids as novel cross-linking bridges | |
| Sechriest et al. | GAG‐augmented polysaccharide hydrogel: A novel biocompatible and biodegradable material to support chondrogenesis | |
| JP4698596B2 (ja) | 濃縮された水性シルクフィブロイン溶液およびそれらの使用 | |
| CN108310467B (zh) | 一种组装型细胞衍生细胞外基质膜复合骨修复材料及其制备方法和应用 | |
| Mohammed et al. | Substrate stiffness and sequence dependent bioactive peptide hydrogels influence the chondrogenic differentiation of human mesenchymal stem cells | |
| Dong et al. | Demineralized and decellularized bone extracellular matrix-incorporated electrospun nanofibrous scaffold for bone regeneration | |
| US7105580B2 (en) | Porous structures useful for growing living tissue, and methods of manufacture | |
| WO2004062697A2 (en) | Silk fibroin materials and use thereof | |
| WO2014133027A1 (ja) | ハイドロゲル | |
| Yang et al. | Preparation and characterization of macromolecule cross-linked collagen hydrogels for chondrocyte delivery | |
| Gao et al. | Directing osteogenic differentiation of BMSCs by cell-secreted decellularized extracellular matrixes from different cell types | |
| Lin et al. | Studies of novel hyaluronic acid-collagen sponge materials composed of two different species of type I collagen | |
| Li et al. | L-polylactic acid porous microspheres enhance the mechanical properties and in vivo stability of degummed silk/silk fibroin/gelatin scaffold | |
| Fan et al. | Ectopic cartilage formation induced by mesenchymal stem cells on porous gelatin-chondroitin-hyaluronate scaffold containing microspheres loaded with TGF-β1 | |
| RU2770558C2 (ru) | Способ создания тканеинженерных конструкций методом биопечати биочернилами для регенерации хрящевой ткани в условиях организма | |
| Theerathanagorn et al. | In vitro human chondrocyte culture on plasma-treated poly (glycerol sebacate) scaffolds | |
| Thompson et al. | Natural Materials for Cell-Based Therapies | |
| Fadilah et al. | Physicochemical properties of gelatin/hyaluronic acid-printed hydrogel incorporating thymoquinone | |
| Vishwanath | Development of silk fibroin/chitosan based porous scaffolds for cartilage tissue engineering | |
| Berber | The effect of Wharton’s jelly extracellular matrix/tannic acid supplementation on porous gelatin foams | |
| JP2017507669A (ja) | 細胞培養用材料、製造方法及びその使用 | |
| CN119455121A (zh) | 一种复合水凝胶同轴支架 | |
| de Carvalho | Development of hyaluronic acid, dextrin and extracellular matrix hydrogels for cell expansion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230711 |
|
| EEER | Examination request |
Effective date: 20230711 |